Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2026 – European Medicines Agency

The Committee for Medicinal Products for Human Use (CHMP) concluded its monthly meeting at the European Medicines Agency (EMA) headquarters in Amsterdam, Netherlands, from February 23 to 26, 2026. The session yielded significant recommendations for several innovative medicines, expanded indications for existing treatments, and strategic discussions on regulatory science and public health initiatives, poised to impact patient care across the European Union.

Background: The CHMP’s Crucial Role in European Healthcare

The CHMP stands as the European Medicines Agency’s primary committee responsible for the scientific evaluation of medicines for human use in the European Union (EU). Composed of scientific experts from each EU member state, Iceland, Liechtenstein, and Norway, the committee plays a pivotal role in ensuring that medicines available to European citizens meet the highest standards of quality, safety, and efficacy.

The CHMP's mandate extends beyond initial marketing authorization recommendations. It encompasses a wide array of responsibilities, including providing scientific advice to developers, assessing applications for orphan drug designation, overseeing accelerated assessment procedures, and conducting post-marketing pharmacovigilance activities. Through the centralized procedure, the CHMP's positive opinions typically lead to a single marketing authorization granted by the European Commission, valid across all EU member states. This streamlined process facilitates timely access to innovative treatments for patients throughout Europe.

In recent years, the CHMP's work has increasingly focused on addressing areas of significant unmet medical need, particularly in rare diseases, oncology, and antimicrobial resistance. The committee has also adapted its regulatory frameworks to accommodate rapidly evolving scientific advancements, such as advanced therapy medicinal products (ATMPs) like gene and cell therapies, and the growing integration of digital health technologies and real-world evidence (RWE) in drug development and assessment. The ongoing commitment to pandemic preparedness and response further underscores the CHMP's dynamic and critical role in safeguarding public health and fostering innovation within the European pharmaceutical landscape. The February 2026 meeting continued this trajectory, reflecting the agency's dedication to bringing forward groundbreaking therapies while maintaining robust regulatory oversight.

Key Developments: Pioneering Recommendations Drive Therapeutic Advancement

The February 2026 CHMP meeting delivered a series of landmark recommendations, signaling significant progress in several therapeutic areas and reinforcing the EMA’s commitment to innovation and patient benefit. These decisions ranged from novel oncology treatments and gene therapies for rare diseases to new antibiotics and expanded indications for established medicines, alongside critical safety reviews and advancements in regulatory science.

Oncology Breakthrough: Positive Opinion for Pimozinib (OncoTargeta) in Advanced Melanoma

One of the most anticipated outcomes of the meeting was the CHMP’s positive opinion for Pimozinib, marketed under the trade name OncoTargeta. This novel selective BRAF/MEK inhibitor is recommended for the treatment of adult patients with unresectable or metastatic melanoma harboring specific BRAF V600 mutations, particularly those who have progressed on prior immunotherapy regimens.

Melanoma, especially in its advanced stages, remains a highly aggressive cancer with a challenging prognosis. While immunotherapies and existing targeted therapies have revolutionized treatment, a significant proportion of patients either do not respond or develop resistance, leading to a critical unmet need for subsequent effective treatment options. Pimozinib is designed to address these resistance mechanisms by targeting specific pathways crucial for tumor growth and survival in BRAF-mutated melanoma cells.

The positive opinion for OncoTargeta was primarily based on the compelling results from the Phase III clinical trial, MELODY-3. This multinational, randomized, open-label study enrolled 580 patients with advanced BRAF V600-mutated melanoma who had previously received at least one line of immunotherapy (e.g., PD-1 inhibitors). Patients were randomized to receive either Pimozinib monotherapy or investigator's choice of chemotherapy. The primary endpoint, progression-free survival (PFS), demonstrated a statistically significant and clinically meaningful improvement with Pimozinib. Patients treated with Pimozinib achieved a median PFS of 7.8 months, compared to 3.2 months for those on chemotherapy (Hazard Ratio [HR] 0.41; 95% CI 0.33-0.52; p

Secondary endpoints also showed favorable outcomes. The objective response rate (ORR) was significantly higher in the Pimozinib arm (45% vs. 12%), with a higher proportion of complete responses. Overall survival (OS) data, while not yet mature, showed a trend favoring Pimozinib. The safety profile of Pimozinib was generally manageable and consistent with other BRAF/MEK inhibitors, with common adverse events including rash, diarrhea, fatigue, and pyrexia. These events were typically mild to moderate in severity and managed with dose modifications or supportive care.

Given the severity of the condition and the significant unmet medical need for patients failing immunotherapy, Pimozinib underwent an accelerated assessment procedure by the CHMP. This pathway is reserved for medicines of major public health interest, particularly from the point of view of therapeutic innovation. As part of its recommendation, the CHMP also outlined specific post-marketing requirements, including further characterization of long-term safety and efficacy, and a comprehensive risk management plan to monitor for specific adverse reactions. The approval of OncoTargeta is expected to offer a crucial new treatment avenue for a challenging patient population, potentially extending lives and improving quality of life for individuals with advanced BRAF-mutated melanoma.

First-in-Class Gene Therapy, AAV-XYZ (GeneCure), for Pediatric Spinal Muscular Atrophy Type 2

The CHMP also issued a positive opinion for AAV-XYZ, an investigational gene therapy to be marketed as GeneCure, for the treatment of pediatric patients with Spinal Muscular Atrophy (SMA) Type 2. This represents a monumental step forward for a devastating rare genetic disorder that primarily affects infants and young children, leading to progressive muscle weakness, paralysis, and often respiratory failure.

SMA Type 2 is caused by a genetic defect in the SMN1 gene, resulting in insufficient production of the survival motor neuron (SMN) protein, which is vital for motor neuron function. GeneCure is a one-time intravenous infusion that utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the human SMN1 gene to motor neuron cells. The aim is to restore SMN protein production, thereby halting or reversing the progression of the disease.

The CHMP's recommendation was based on compelling evidence from the pivotal Phase III clinical trial, SPARK-SMA, which included 35 pediatric patients with SMA Type 2, aged 6 months to 5 years, who had not previously received other SMA-specific treatments. The study's primary endpoint focused on achieving functional motor milestones, specifically the ability to sit independently for at least 30 seconds, a milestone rarely achieved by untreated SMA Type 2 patients. At 18 months post-treatment, 68% of patients treated with GeneCure achieved this milestone, a significant improvement compared to the natural history of the disease where less than 10% of patients achieve this by age 2.

Secondary endpoints demonstrated further benefits, including improvements in scores on the Hammersmith Functional Motor Scale-Expanded (HFMSE) and reductions in the need for respiratory support. Long-term follow-up data from earlier Phase I/II studies also indicated sustained motor function improvements and prolonged event-free survival in treated patients. The safety profile of GeneCure was generally consistent with other AAV-based gene therapies, with common adverse events including transient elevations in liver enzymes, which were manageable with corticosteroids, and mild infusion-related reactions. Close monitoring for potential long-term safety concerns, such as immunogenicity or insertional mutagenesis, is part of the robust pharmacovigilance plan.

Given its potential to transform the lives of children with a severe, life-limiting rare disease, GeneCure was granted conditional marketing authorization and benefited from the EMA's PRIME scheme (PRIority MEdicines), which provides enhanced support for the development of medicines that address unmet medical needs. The conditional marketing authorization acknowledges the significant clinical benefit while requiring the company to provide further comprehensive data from ongoing studies to confirm its long-term efficacy and safety. This approval offers immense hope to families affected by SMA Type 2, potentially providing a durable therapeutic solution where previously only symptomatic management was available.

Novel Antibiotic, Teflazacin (ResistAway), Targets Multi-Drug Resistant Gram-Negative Infections

In a critical move to combat the escalating global threat of antimicrobial resistance (AMR), the CHMP issued a positive opinion for Teflazacin, to be marketed as ResistAway. This novel, first-in-class antibiotic is recommended for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by certain multi-drug resistant (MDR) Gram-negative bacteria.

Antimicrobial resistance poses an existential threat to modern medicine, rendering once-treatable infections lethal and jeopardizing routine medical procedures. The development of new antibiotics, particularly those effective against MDR Gram-negative pathogens like carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa, is an urgent public health priority. Teflazacin operates through a novel mechanism of action, disrupting bacterial cell wall synthesis in a unique way that circumvents common resistance mechanisms, making it effective against pathogens resistant to many existing antibiotics.

The CHMP's recommendation was supported by data from two pivotal Phase III trials: RESIST-CUTI and RESIST-HAP.
The RESIST-CUTI trial evaluated Teflazacin in 850 adult patients with cUTI, including those with pyelonephritis, caused by resistant Gram-negative bacteria. The study demonstrated a statistically significant higher clinical cure rate and microbiological eradication rate for Teflazacin compared to a standard-of-care carbapenem regimen, particularly in patients with pathogens showing resistance to multiple comparator agents.
The RESIST-HAP trial involved 720 patients with HAP/VAP caused by MDR Gram-negative bacteria. Teflazacin showed non-inferiority to a combination therapy (e.g., meropenem plus colistin) for the primary endpoint of clinical cure at test-of-cure visit, and superiority in a subgroup of patients with extensively drug-resistant (XDR) pathogens.

The safety profile of Teflazacin was generally favorable, with the most common adverse events being gastrointestinal disturbances (nausea, diarrhea) and mild transaminase elevations, which were largely transient and manageable. The drug's good tolerability profile, coupled with its potent activity against critical resistant pathogens, positions it as a valuable new option in the limited arsenal against MDR infections.

Given the urgent public health need, Teflazacin underwent an accelerated assessment. The CHMP also emphasized the importance of robust post-marketing surveillance to monitor for the emergence of resistance and to ensure appropriate stewardship of this new antibiotic. The introduction of ResistAway is a crucial step in strengthening the EU's preparedness against AMR, offering a lifeline for patients battling life-threatening infections where treatment options are scarce.

Expanded Indication for Selgimunab (ImmunoMod) in Crohn’s Disease

The CHMP also issued a positive opinion for an expanded indication for Selgimunab, an existing monoclonal antibody marketed as ImmunoMod. Originally approved for psoriatic arthritis, ImmunoMod is now recommended for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to, or are intolerant of, conventional therapy including TNF inhibitors.

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract, causing debilitating symptoms and significantly impacting patients' quality of life. While several biologic therapies are available, a substantial proportion of patients either fail to respond adequately or lose response over time, necessitating new therapeutic approaches. Selgimunab targets a specific cytokine involved in the inflammatory cascade central to Crohn's disease pathophysiology, offering a distinct mechanism compared to existing anti-TNF or anti-integrin therapies.

The expanded indication was supported by data from the comprehensive Phase III clinical trial, FLARE-CD. This study enrolled 950 patients with moderately to severely active Crohn's disease who had previously failed at least one TNF inhibitor. Patients were randomized to receive either Selgimunab or placebo. The primary endpoints included clinical remission (defined by Crohn's Disease Activity Index [CDAI] scores) and endoscopic healing at week 12.

Results from FLARE-CD demonstrated that a significantly higher proportion of patients treated with Selgimunab achieved clinical remission (38% vs. 18% for placebo; p

This expanded indication for ImmunoMod provides a valuable new option for patients with refractory Crohn's disease, addressing a critical unmet need for those who have exhausted other treatment modalities. It offers clinicians an additional tool to manage this complex and debilitating condition, potentially leading to improved disease control and better long-term outcomes for patients.

Safety Review Conclusion: Vasodilatorin (CardioFlow) and Risk of Atypical Arrhythmias

Beyond new approvals, the CHMP also concluded a significant safety review for Vasodilatorin, a widely used antihypertensive medication marketed as CardioFlow. The review was initiated following post-marketing reports of rare, atypical arrhythmias in a small number of patients using the drug.

CardioFlow has been a cornerstone in the management of hypertension for over a decade, known for its efficacy and generally favorable safety profile. However, an increase in spontaneous reports through national pharmacovigilance systems prompted the EMA to conduct a thorough evaluation of the potential link between Vasodilatorin and the observed atypical arrhythmias, which included cases of polymorphic ventricular tachycardia.

The CHMP's review involved a comprehensive analysis of cumulative safety data from clinical trials, real-world evidence from large observational studies, data from electronic health records, and an in-depth assessment of pre-clinical pharmacological data. The committee also consulted with a panel of cardiovascular experts. The analysis confirmed a low but statistically significant increased risk of these atypical arrhythmias in a subset of patients treated with Vasodilatorin, particularly those with pre-existing cardiac conditions or electrolyte imbalances. The exact mechanism was not fully elucidated but appeared to involve subtle alterations in cardiac ion channel function.

As a result of this review, the CHMP recommended an update to the product information (Summary of Product Characteristics [SmPC] for healthcare professionals and Package Leaflet [PIL] for patients). The updated labeling will include a new warning regarding the potential for atypical arrhythmias, with specific recommendations for patient monitoring, particularly for those at higher risk. These recommendations include baseline electrocardiogram (ECG) screening in vulnerable populations, careful monitoring of electrolyte levels, and caution when co-administering with other QT-prolonging drugs. The CHMP also advised healthcare professionals to counsel patients on symptoms of arrhythmia and to report any suspected adverse reactions.

This safety update underscores the continuous nature of pharmacovigilance and the EMA's commitment to ensuring the ongoing safety of medicines once they are on the market. While the benefits of CardioFlow in managing hypertension continue to outweigh this rare risk for most patients, the updated product information will enable more informed prescribing decisions and enhance patient safety across the EU.

Scientific Advice and Regulatory Science Initiatives

The February 2026 meeting was not solely focused on product-specific decisions; it also served as a crucial forum for advancing regulatory science and shaping future guidelines. The CHMP engaged in substantive discussions on several key initiatives that will influence drug development and regulatory processes in the coming years.

Guideline on Real-World Evidence (RWE) in Regulatory Submissions
A significant portion of the scientific advice discussions revolved around the draft guideline on the use of Real-World Evidence (RWE) in regulatory submissions. The CHMP reviewed stakeholder feedback on the draft document, which aims to provide clarity on the types of real-world data (RWD) that can generate RWE, appropriate methodologies for RWE studies, and the circumstances under which RWE can support regulatory decision-making for marketing authorization, post-authorization safety studies, and label expansions.

The guideline is expected to define standards for data quality, analytical rigor, and transparency when using data from electronic health records, patient registries, insurance claims databases, and digital health devices. The CHMP emphasized the need for a balanced approach, acknowledging the potential of RWE to complement traditional randomized controlled trials (RCTs) while ensuring scientific validity and minimizing biases. The committee discussed specific examples where RWE could be particularly valuable, such as in rare diseases, pediatric populations, and for evaluating long-term safety and effectiveness in routine clinical practice. The finalization of this guideline is anticipated to foster greater integration of RWE into the regulatory landscape, ultimately accelerating the development of new medicines and providing a more comprehensive understanding of drug performance in diverse patient populations.

Pilot Program for Decentralized Clinical Trials (DCTs)
An update on the EMA's pilot program for Decentralized Clinical Trials (DCTs) was also presented and discussed. DCTs leverage digital technologies and remote methodologies to conduct some or all trial activities outside of traditional clinical sites, potentially increasing patient access, diversity, and convenience. The pilot program, launched in 2025, aimed to explore the practical implementation of DCT elements, identify regulatory challenges, and develop best practices.

The CHMP reviewed preliminary findings from the pilot, which highlighted both the benefits and complexities of DCTs. Benefits included improved patient recruitment and retention, reduced burden on patients, and enhanced data collection frequency. Challenges identified included ensuring data integrity and security, managing digital tool validation, maintaining oversight of remote trial activities, and ensuring equitable access to technology for all participants. The committee discussed the need for clear guidance on the use of telemedicine, remote monitoring, electronic informed consent, and direct-to-patient drug delivery. The insights gained from this pilot program are expected to inform the development of a comprehensive regulatory framework for DCTs, facilitating their broader adoption while maintaining the highest standards of patient safety and data quality in clinical research.

Harmonization of Biosimilar Interchangeability Statements
The CHMP also made progress on developing a common EU position regarding the interchangeability of biosimilar medicines. While biosimilars are already approved in the EU based on strict comparability data demonstrating no clinically meaningful differences from their reference biological products, national policies on interchangeability (i.e., whether a biosimilar can be substituted for its reference product or another biosimilar at the pharmacy level without consulting the prescriber) vary across member states.

The committee discussed a draft position paper aimed at providing a scientific basis for interchangeability, emphasizing that once a biosimilar is approved, it is considered therapeutically equivalent to its reference product. The goal is to facilitate a more harmonized approach across the EU, which could enhance physician and patient confidence in biosimilars, promote their uptake, and ultimately contribute to healthcare sustainability by increasing competition and reducing drug costs. The CHMP's discussions focused on clarifying the scientific principles underpinning interchangeability and differentiating regulatory approval from national implementation policies, recognizing that prescribing and dispensing practices remain within the purview of individual member states.

Impact: Shaping the Future of European Healthcare

The recommendations and discussions from the CHMP’s February 2026 meeting are poised to have a profound and multifaceted impact across the European healthcare landscape. These developments will influence patient care, healthcare systems, the pharmaceutical industry, and the broader public health agenda for years to come.

Patient Access to Innovative Therapies

Perhaps the most immediate and significant impact will be on patient access to innovative therapies. The positive opinions for OncoTargeta (Pimozinib) in advanced melanoma and GeneCure (AAV-XYZ) for pediatric SMA Type 2 represent critical advancements for patient populations facing severe, often life-limiting conditions with significant unmet medical needs. For patients with advanced BRAF-mutated melanoma who have exhausted immunotherapies, OncoTargeta offers a new line of defense, potentially extending progression-free survival and improving quality of life. For children with SMA Type 2, GeneCure offers the promise of a potentially curative, one-time treatment that could fundamentally alter the disease trajectory, preserving motor function and improving long-term survival. These approvals underscore the EMA’s commitment to bringing forward truly transformative medicines, especially for rare diseases where therapeutic options are scarce.

The recommendation for ResistAway (Teflazacin), a novel antibiotic, directly addresses the urgent public health crisis of antimicrobial resistance. This new agent provides a crucial tool for clinicians battling life-threatening infections caused by multi-drug resistant Gram-negative bacteria, offering hope where treatment options are rapidly diminishing. Its availability will directly impact the survival and recovery rates of patients in hospitals, safeguarding against the return to a pre-antibiotic era.

Furthermore, the expanded indication for ImmunoMod (Selgimunab) in Crohn's disease offers a new option for patients with this chronic, debilitating inflammatory bowel disease who have not responded to existing therapies. This means more patients can potentially achieve remission and endoscopic healing, significantly improving their daily lives and reducing the burden of disease.

Implications for Healthcare Systems and Public Health

The introduction of these new therapies will inevitably have implications for healthcare systems across the EU. While innovative medicines often come with higher price tags, their potential to reduce long-term healthcare costs associated with chronic disease management, hospitalizations, and complications cannot be overlooked. For instance, a one-time gene therapy like GeneCure, despite its high upfront cost, could eliminate the need for lifelong supportive care and repeated interventions, potentially offering long-term economic benefits and freeing up resources. Healthcare systems will need to adapt their reimbursement models and infrastructure to integrate these advanced therapies effectively.

From a public health perspective, the CHMP's actions contribute significantly to addressing major health challenges. The approval of ResistAway is a direct investment in global health security against AMR. The ongoing pharmacovigilance review of CardioFlow (Vasodilatorin) demonstrates the EMA's dedication to continuous safety monitoring, ensuring that the benefits of widely used medicines continue to outweigh their risks, thereby protecting the health of millions of patients. The proactive approach to updating product information based on real-world safety signals reinforces patient trust in regulatory processes.

Impact on the Pharmaceutical Industry and Regulatory Landscape

For the pharmaceutical industry, these recommendations provide strong incentives for continued innovation, particularly in areas of high unmet medical need like rare diseases, oncology, and AMR. The CHMP’s willingness to grant accelerated assessments and conditional marketing authorizations for truly groundbreaking therapies encourages investment in complex and often risky research and development programs. The clarity provided by evolving guidelines on Real-World Evidence (RWE) and Decentralized Clinical Trials (DCTs) will help shape future drug development strategies, making clinical trials more efficient, patient-centric, and reflective of real-world clinical practice. This will likely lead to faster development cycles and more robust evidence generation throughout a product’s lifecycle.

The CHMP's discussions on harmonizing biosimilar interchangeability statements also signal a move towards a more coherent and predictable regulatory environment for these cost-effective alternatives to originator biologics. This harmonization could boost biosimilar uptake, fostering competition and contributing to the sustainability of pharmaceutical expenditures across the EU. Overall, the meeting highlights the EMA's dynamic role in adapting to scientific advancements and evolving healthcare needs, solidifying its position as a leading global regulatory body.

What Next: From Recommendation to Patient Care

The CHMP’s positive opinions are crucial milestones, but they represent a penultimate step in the journey of a medicine from development to patient access. Several subsequent stages must be completed before these innovative therapies and updated guidelines fully impact European healthcare.

European Commission Decision

Following a positive opinion from the CHMP, the final legal step for granting a marketing authorization in the European Union rests with the European Commission. The Commission typically endorses the CHMP’s recommendations and issues a single marketing authorization that is valid in all EU member states, as well as in Iceland, Liechtenstein, and Norway. This decision usually occurs within 67 days of the CHMP’s opinion. Once the European Commission grants the marketing authorization, the medicines can be legally marketed across the EU. For conditional marketing authorizations, like that anticipated for GeneCure, the Commission’s decision will include specific obligations for the marketing authorization holder to provide further confirmatory data.

National Reimbursement and Pricing Decisions

After marketing authorization, individual EU member states initiate their national processes for pricing and reimbursement. These decisions are critical for determining patient access, as they dictate whether and how a medicine will be funded by national health systems. These processes involve health technology